Stock listing
NASDAQ:LABT Lakewood-Amedex Biotherapeutics Inc. Stock
Home listing (NASDAQ) of Lakewood-Amedex Biotherapeutics Inc.
Follow Lakewood-Amedex Biotherapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LABT
$0.245 USD +0.005 (+2.0%)
Close on Nov 20, 2026
- Day range
- $0.221 – $0.307 USDNov 20, 2026
- Volume
- 57.47M sharesNov 20, 2026
- Market cap
- $580,337 USDAt the close on Nov 20, 2026 · price × 2.37M shares outstanding
- Traded on an average day
- $9.01M USDMedian day 328,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LABT · Home | $0.245 USD | +0.005 (+2.0%) | 57,471,326 | $0.232 | $0.307 | $0.221 | $0.240 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LABT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.245 | +0.005 | +2.0% | $0.232 | $0.307 | $0.221 | 57,471,326 | |
| $0.240 | +0.025 | +11.9% | $0.227 | $0.308 | $0.192 | 5,039,832 | |
| $0.215 | -0.005 | -2.2% | $0.207 | $0.269 | $0.204 | 1,977,326 | |
| $0.219 | -0.063 | -22.3% | $0.258 | $0.259 | $0.212 | 874,059 | |
| $0.282 | -0.077 | -21.4% | $0.334 | $0.339 | $0.240 | 2,024,462 | |
| $0.359 | -0.041 | -10.2% | $0.373 | $0.390 | $0.350 | 1,159,890 | |
| $0.400 | -0.020 | -4.8% | $0.410 | $0.440 | $0.360 | 2,731,700 | |
| $0.420 | 0.000 | 0.0% | $0.360 | $0.440 | $0.350 | 4,376,800 | |
| $0.420 | +0.030 | +7.7% | $0.440 | $0.450 | $0.370 | 13,547,700 | |
| $0.390 | -0.150 | -27.8% | $0.440 | $0.490 | $0.330 | 36,109,700 | |
| $0.540 | +0.350 | +184.2% | $0.380 | $0.960 | $0.370 | 753,749,700 | |
| $0.190 | -0.010 | -5.0% | $0.190 | $0.200 | $0.170 | 809,100 | |
| $0.200 | +0.010 | +5.3% | $0.180 | $0.200 | $0.170 | 880,800 | |
| $0.190 | -0.010 | -5.0% | $0.190 | $0.200 | $0.170 | 1,361,400 | |
| $0.200 | -0.040 | -16.7% | $0.200 | $0.220 | $0.200 | 1,935,900 | |
| $0.240 | -0.050 | -17.2% | $0.240 | $0.240 | $0.220 | 4,128,300 | |
| $0.290 | 0.000 | 0.0% | $0.280 | $0.290 | $0.250 | 24,887,400 | |
| $0.290 | +0.010 | +3.6% | $0.250 | $0.290 | $0.240 | 1,423,200 | |
| $0.280 | -0.030 | -9.7% | $0.270 | $0.280 | $0.240 | 2,789,800 | |
| $0.310 | -0.180 | -36.7% | $0.350 | $0.360 | $0.280 | 40,069,500 | |
| $0.490 | +0.020 | +4.3% | $0.470 | $0.510 | $0.460 | 328,400 | |
| $0.470 | -0.110 | -19.0% | $0.550 | $0.580 | $0.420 | 658,900 | |
| $0.580 | 0.000 | 0.0% | $0.580 | $0.620 | $0.570 | 99,600 | |
| $0.580 | 0.000 | 0.0% | $0.580 | $0.670 | $0.560 | 93,100 | |
| $0.580 | -0.030 | -4.9% | $0.630 | $0.630 | $0.580 | 65,600 | |
| $0.610 | -0.020 | -3.2% | $0.600 | $0.630 | $0.580 | 148,300 | |
| $0.630 | -0.060 | -8.7% | $0.670 | $0.710 | $0.620 | 133,900 | |
| $0.690 | -0.040 | -5.5% | $0.730 | $0.730 | $0.670 | 152,700 | |
| $0.730 | -0.050 | -6.4% | $0.770 | $0.770 | $0.730 | 160,700 | |
| $0.780 | -0.010 | -1.3% | $0.790 | $0.820 | $0.780 | 118,100 | |
| $0.790 | -0.060 | -7.1% | $0.820 | $0.830 | $0.780 | 216,800 | |
| $0.850 | -0.020 | -2.3% | $0.780 | $0.900 | $0.760 | 8,498,700 | |
| $0.870 | +0.020 | +2.4% | $0.860 | $0.870 | $0.830 | 149,700 | |
| $0.850 | -0.080 | -8.6% | $0.880 | $0.890 | $0.820 | 272,200 | |
| $0.930 | 0.000 | 0.0% | $0.930 | $0.950 | $0.910 | 120,500 | |
| $0.930 | -0.030 | -3.1% | $0.940 | $0.960 | $0.910 | 170,300 | |
| $0.960 | -0.030 | -3.0% | $0.970 | $0.980 | $0.920 | 401,800 | |
| $0.990 | -0.160 | -13.9% | $1.090 | $1.090 | $0.920 | 1,288,600 | |
| $1.150 | -0.520 | -31.1% | $2.060 | $2.130 | $1.100 | 35,362,700 | |
| $1.670 | -0.160 | -8.7% | $1.850 | $1.850 | $1.630 | 176,000 | |
| $1.830 | +0.050 | +2.8% | $1.760 | $1.850 | $1.690 | 101,500 | |
| $1.780 | -0.210 | -10.6% | $1.970 | $2.000 | $1.780 | 109,800 | |
| $1.990 | -0.060 | -2.9% | $2.080 | $2.100 | $1.900 | 128,400 | |
| $2.050 | +0.060 | +3.0% | $1.990 | $2.080 | $1.920 | 361,800 | |
| $1.990 | +0.130 | +7.0% | $1.920 | $2.150 | $1.890 | 281,200 | |
| $1.860 | -0.230 | -11.0% | $2.040 | $2.050 | $1.840 | 125,200 | |
| $2.090 | -0.080 | -3.7% | $2.180 | $2.180 | $2.080 | 54,500 | |
| $2.170 | +0.050 | +2.4% | $2.170 | $2.170 | $2.070 | 97,300 | |
| $2.120 | -0.100 | -4.5% | $2.250 | $2.280 | $2.060 | 56,400 | |
| $2.220 | +0.170 | +8.3% | $2.110 | $2.230 | $2.030 | 141,000 | |
| $2.050 | -0.270 | -11.6% | $2.240 | $2.300 | $2.030 | 286,600 | |
| $2.320 | +0.140 | +6.4% | $2.200 | $2.610 | $2.130 | 5,084,500 | |
| $2.180 | +0.300 | +16.0% | $1.890 | $2.270 | $1.890 | 500,000 | |
| $1.880 | -0.020 | -1.1% | $1.880 | $1.980 | $1.870 | 90,200 | |
| $1.900 | -0.170 | -8.2% | $2.100 | $2.160 | $1.860 | 251,200 | |
| $2.070 | -0.690 | -25.0% | $2.470 | $2.640 | $2.060 | 509,100 | |
| $2.760 | +0.260 | +10.4% | $2.680 | $2.860 | $2.530 | 3,568,500 | |
| $2.500 | +0.200 | +8.7% | $2.230 | $2.580 | $2.220 | 13,655,500 | |
| $2.300 | -0.190 | -7.6% | $2.440 | $2.440 | $2.220 | 95,800 | |
| $2.490 | +0.040 | +1.6% | $2.620 | $2.620 | $2.350 | 213,500 | |
| $2.450 | +0.160 | +7.0% | $2.230 | $2.570 | $2.200 | 377,200 | |
| $2.290 | +0.160 | +7.5% | $2.100 | $2.350 | $2.100 | 213,343 | |
| $2.130 | -0.110 | -4.9% | $2.200 | $2.290 | $2.100 | 39,957 | |
| $2.240 | +0.050 | +2.3% | $2.180 | $2.340 | $2.170 | 70,500 | |
| $2.190 | -0.050 | -2.2% | $2.170 | $2.240 | $2.130 | 85,100 |
Splits
1 split · NASDAQ:LABT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:LABT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
Latest deck · Oct 21, 2026
Investor Presentation (October 2026)
Investor deck · 22 slides
Latest news
Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
Nov 5, 2026
Closed $0.54 (+184.2%) on Nov 5, 2026
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
Oct 21, 2026
Closed $0.47 (-19.0%) on Oct 21, 2026
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Oct 7, 2026
Closed $0.85 (-2.3%) on Oct 7, 2026
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
Oct 1, 2026
Closed $0.93 (-3.1%) on Oct 1, 2026
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
Sep 28, 2026
Closed $1.15 (-31.1%) on Sep 28, 2026
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Sep 21, 2026
Closed $2.05 (+3.0%) on Sep 21, 2026
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
Sep 18, 2026
Closed $1.99 (+7.0%) on Sep 18, 2026
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $2.18 (+16.0%) on Sep 8, 2026
Lakewood-Amedex Biotherapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 20 in all · newest Nov 5, 2026 · oldest 2026
- Decks
- 4 decks · latest Oct 21, 2026
Where Lakewood-Amedex Biotherapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LABT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LABT | BOATS | United States | USD |
Valuation
Price/book 0.2× against a median of 0.2×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.74M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.46
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABT | US$580,337 | −US$2.74M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.46 |
| Biodexa Pharmaceuticals plc · NASDAQ:BDRX | US$982,950 | −US$3.22M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.01 |
| Gabather AB · OMXSTO:GABA | US$919,514 | US$559,105 | n/a | n/a | n/a | 6.4× | n/a | 0.0× | n/a |
| ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2 | US$792,634 | −US$2.43M | n/a | −6.5× | n/a | 0.2× | −935.9% | 0.0× | n/a |
| Silexion Therapeutics Corp · NASDAQ:SLXN | US$790,001 | −US$3.60M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 2.77 |
| Oragenics Inc. · AMEX:OGEN | US$708,377 | −US$1.12M | n/a | n/a | n/a | 0.7× | n/a | 0.4× | 1.47 |
| Protagenic Therapeutics, Inc. · OTC:PTIX | US$687,879 | US$610,970 | 0.1× | n/a | n/a | 0.6× | n/a | 0.0× | 1.21 |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Altamira Therapeutics Ltd. · OTC:CYTOF | US$404,655 | US$400,900 | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.64 |
| NKGen Biotech Inc. · OTC:NKGN | US$391,807 | US$38.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.88 |
| Median of the others | US$698,128 | −US$360,759 | 0.1× | −3.3× | 0.2× | −558.9% | 0.0× | 1.23 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.96 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Kelvin Cooper | Chief Executive Officer, Director |
| Peter F. Ceccacci | Chief Financial Officer |
| Thomas Balzer | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Doug Manion | Chairman of the Board |
| Joseph Tucker | Director |
| Kelvin Cooper | Chief Executive Officer, Director |
| Leonard J. DeRoma | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −2.2% |
| Q2 2026 | Aug 28, 2026 | +0.4% |
| Q1 2026 | Jun 3, 2026 | +9.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 22 slides | Oct 21, 2026 |
| Investor Presentation (September 2026) | Investor deck | 21 slides | Sep 25, 2026 |
| Investor Presentation (July 2026) | Investor deck | 21 slides | Jul 15, 2026 |
| Lakewood-Amedex — Investor Presentation (September 2014) | Investor deck | 31 slides | September 2014 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Research and development | 1.26M | 2.10M | 5.53M |
| Selling, general and administrative | 2.51M | 1.92M | 3.10M |
| Operating income | -3.77M | -4.03M | -8.64M |
| Depreciation and amortization | 120.0K | 118.6K | 121.0K |
| EBITDA | -3.65M | -3.91M | -8.52M |
| Interest expense | 1.31K | 5.00K | 10.0K |
| Income before tax | -3.85M | -4.86M | -8.28M |
| Net income | -3.85M | -4.86M | -8.28M |
| Earnings per share, basic | -5.50 | -6.94 | -11.84 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 236.4K | 681.1K | 2.53M |
| Short-term investments | 0 | 3.86M | |
| Current assets | 305.4K | 774.0K | 6.48M |
| Property, plant and equipment | 9.22K | ||
| Total assets | 481.6K | 1.07M | 6.89M |
| Accounts payable | 381.0K | 166.5K | 499.1K |
| Current liabilities | 2.41M | 500.6K | 2.06M |
| Total debt | 1.66M | ||
| Total liabilities | 2.45M | 661.0K | 2.34M |
| Shareholders' equity | -1.96M | 409.6K | 4.56M |
| Shares outstanding | 699.6K | 699.5K | 699.5K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -1.94M | -5.72M | -6.82M |
| Capital spending | 0 | -1.85K | 0 |
| Free cash flow | -1.94M | -5.73M | -6.82M |
| Cash from financing | 1.50M | -50.0K | 0 |
| Share buybacks | 0 | -50.0K | 0 |
| Change in cash | -444.7K | -1.85M | -10.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 8-K · Current report | Nov 10, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 28, 2026 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Sep 25, 2026 | Other filings | SEC |
| S-1 · Registration statement | Sep 18, 2026 | Offer document | SEC |
| DRS · Draft registration statement | Aug 21, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 17, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
All 47 filings
Cap table
Built by 6ix from Lakewood-Amedex Biotherapeutics Inc.’s releases · as of Aug 3, 2026
- Common shares
- 2,369,688
- Fully diluted
- 2,369,688
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,369,688 | Aug 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Aug 3, 2026 | 2,369,688 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Joseph Tucker Other companies: Enveric Biosciences, Inc. (Chief Executive Officer, Director · Since at least Sep 16, 2021) | Director · Since at least Apr 24, 2026 |
| Doug Manion | Chairman of the Board · Since at least Apr 23, 2026 |
| Kelvin Cooper | Chief Executive Officer, Director · Since at least Apr 17, 2026 |
| Leonard J. DeRoma | Director · Since at least Apr 17, 2026 |
| Peter F. Ceccacci | Chief Financial Officer · Since at least Apr 17, 2026 |
| Thomas Balzer | Chief Medical Officer · Since at least Apr 17, 2026 |
Log in to ask 6ix AI your own questions about Lakewood-Amedex Biotherapeutics Inc.